-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
527 ，，2020，7.
29%。TOP101，70%，。，201910；，10。，、、610%。，TOP107，、、、。
29%。TOP101，70%，。，201910；，10。，、、610%。，TOP107，、、、。
TOP10！、……7“”
：
According to data from Menet.
com, in recent years , the sales of proprietary Chinese medicine plasters in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased.
In 2020, despite the impact of the new crown epidemic, they still To achieve a year-on-year increase of 7.
29%.
From the perspective of sales channels, the market share of urban public hospitals, county-level public hospitals, and township hospitals all declined slightly, while urban community centers grew rapidly.
com, in recent years , the sales of proprietary Chinese medicine plasters in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased.
In 2020, despite the impact of the new crown epidemic, they still To achieve a year-on-year increase of 7.
29%.
From the perspective of sales channels, the market share of urban public hospitals, county-level public hospitals, and township hospitals all declined slightly, while urban community centers grew rapidly.
2020 Top 10 Chinese Patent Medicine Plaster Products in Public Medical Institutions in China's Urban Public Medical Institutions
Source: Terminal competition landscape of China's public medical institutions
The sales of TOP10 products all exceed 100 million yuan, accounting for more than 70% of the market share of proprietary Chinese medicine plasters, and the market concentration is relatively high.
Among them, the sales of Yunnan Baiyao ointment broke the 1 billion mark in 2019 and reached a new high in 2020; Xiaotong Plaster followed closely and became the second product exceeding 1 billion.
From the perspective of treatment category, orthopedic analgesics accounted for half of the country.
It is worth mentioning that 7 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other companies.
Among them, the sales of Yunnan Baiyao ointment broke the 1 billion mark in 2019 and reached a new high in 2020; Xiaotong Plaster followed closely and became the second product exceeding 1 billion.
From the perspective of treatment category, orthopedic analgesics accounted for half of the country.
It is worth mentioning that 7 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other companies.
Yunnan Baiyao Ointment hit a new high! The second 1 billion Chinese patent medicine plaster was born
Sales of Yunnan Baiyao Ointment in Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Yunnan Baiyao Ointment is an exclusive product of Yunnan Baiyao, which is used for bruises, blood stasis, swelling pain, and rheumatic pain.
According to data from Menet.
com, after the sales of Yunnan Baiyao Ointment in China's public medical institutions exceeded the 1 billion mark in 2019, it will hit a new high in 2020, with a year-on-year increase of more than 15%.
According to data from Menet.
com, after the sales of Yunnan Baiyao Ointment in China's public medical institutions exceeded the 1 billion mark in 2019, it will hit a new high in 2020, with a year-on-year increase of more than 15%.
Recently, the official website of Yunnan Baiyao announced that the company has signed a strategic cooperation framework agreement with Shanghai Pharmaceuticals and Tianjin Pharmaceuticals, and plans to establish a "Yuntian • Rejuvenation of China's Excellent Traditional Chinese Medicine Industry Alliance" to jointly develop the Chinese medicine industry.
Dong Ming, CEO of Yunnan Baiyao, said that this strategic cooperation is of great significance to the development of the Chinese medicine industry.
The development of the Chinese medicine business of the three companies has their own advantages, outstanding characteristics, and complements each other.
They will give full play to the synergy effect through strategic cooperation.
From a strategic perspective, we will carry out multi-dimensional cooperation in research, planting, production, and sales to promote the rapid development of corporate business.
At the same time, through the superposition of brand influence, the improvement of the quality standard and evaluation system of Chinese medicine, the joint research and development of the Chinese medicine industry, the innovation of Chinese medicine health products, etc.
, it injects a booster for the development of the Chinese medicine industry and contributes to the development of the Chinese medicine industry.
The national business card contributes its due strength.
Dong Ming, CEO of Yunnan Baiyao, said that this strategic cooperation is of great significance to the development of the Chinese medicine industry.
The development of the Chinese medicine business of the three companies has their own advantages, outstanding characteristics, and complements each other.
They will give full play to the synergy effect through strategic cooperation.
From a strategic perspective, we will carry out multi-dimensional cooperation in research, planting, production, and sales to promote the rapid development of corporate business.
At the same time, through the superposition of brand influence, the improvement of the quality standard and evaluation system of Chinese medicine, the joint research and development of the Chinese medicine industry, the innovation of Chinese medicine health products, etc.
, it injects a booster for the development of the Chinese medicine industry and contributes to the development of the Chinese medicine industry.
The national business card contributes its due strength.
Sales of terminal pain relief plasters in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
Xiaotong Plaster is an exclusive product of Qizheng Tibetan Medicine, which is mainly used for acute and chronic sprains, bruises, bruises, bone hyperplasia, rheumatism and rheumatoid pain.
According to data from Menet.
com, the sales of terminal pain relief plasters in public medical institutions in China have grown steadily in recent years, and will exceed the 1 billion mark in 2020.
According to data from Menet.
com, the sales of terminal pain relief plasters in public medical institutions in China have grown steadily in recent years, and will exceed the 1 billion mark in 2020.
Qizheng Tibetan Medicine pointed out in its annual report that in 2021, the company will continue to promote and deepen the strategic layout of “one axis, two wings and three supports”, with the mission of “strengthening pain relief”, accelerating market coverage and channel sinking, and strengthening refined management And organization building, guided by academics and brand, continuously improve the quality of operation to ensure the sustainable development of the business.
In terms of products, on the basis of Xiaotong Plaster as a strategic product, develop two major products, Baimai Ointment and Qingpeng Ointment, to expand the market share of Tiebanghammer Discrete Plaster, enrich the product portfolio of different channels, and incubate new pain-relieving products Ruyi Treasure Pills, expand the field of analgesia; strengthen the terminal coverage and academic promotion of women and children's products represented by Honghua Ruyi Pills, and combine a series of oral Tibetan medicines to continue to promote the superior therapeutic products of Tibetan medicine.
In terms of channels, we will strengthen urban expansion, channel sinking, develop county and community medical markets, deepen O2O and e-commerce channels, build an online product supply chain system, and establish a diversified business cooperation model layout for online channels.
In terms of marketing model, strengthen the two-wheel drive of academic marketing and brand marketing, further explore online digital marketing models, and consolidate and develop the company's position in the fields of skeletal muscle system, skin, rehabilitation, women and children.
Continue to promote the "Stomach" family digestive system products and the "Lung-protecting" family respiratory system products, integrate the featured diagnosis and treatment plans of Tibetan medicine's dominant diseases, and provide customers with a full range of diagnosis and treatment plans to achieve the common growth of the company's full range of products.
In terms of products, on the basis of Xiaotong Plaster as a strategic product, develop two major products, Baimai Ointment and Qingpeng Ointment, to expand the market share of Tiebanghammer Discrete Plaster, enrich the product portfolio of different channels, and incubate new pain-relieving products Ruyi Treasure Pills, expand the field of analgesia; strengthen the terminal coverage and academic promotion of women and children's products represented by Honghua Ruyi Pills, and combine a series of oral Tibetan medicines to continue to promote the superior therapeutic products of Tibetan medicine.
In terms of channels, we will strengthen urban expansion, channel sinking, develop county and community medical markets, deepen O2O and e-commerce channels, build an online product supply chain system, and establish a diversified business cooperation model layout for online channels.
In terms of marketing model, strengthen the two-wheel drive of academic marketing and brand marketing, further explore online digital marketing models, and consolidate and develop the company's position in the fields of skeletal muscle system, skin, rehabilitation, women and children.
Continue to promote the "Stomach" family digestive system products and the "Lung-protecting" family respiratory system products, integrate the featured diagnosis and treatment plans of Tibetan medicine's dominant diseases, and provide customers with a full range of diagnosis and treatment plans to achieve the common growth of the company's full range of products.
Over 10% ! The 6 major products of Compound Nanxing Pain Relief Ointment and Musk Zhuifeng Pain Relief Ointment are growing rapidly
6 product related information
Source: One-click search on Mi Nei.
com
com
In terms of growth rate, among the TOP10 products, the growth rates of 6 products including Yunnan Baiyao Ointment, Xiaotong Plaster, and Compound Nanxing Pain Relief Ointment all exceeded 10%.
Among them, 4 are exclusive products.
Musk Zhuifeng Analgesic Ointment has the fastest growth rate, exceeding 30%.
Among them, 4 are exclusive products.
Musk Zhuifeng Analgesic Ointment has the fastest growth rate, exceeding 30%.
Sales of Compound Nanxing Pain Relief Ointment on the Terminal of Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Compound Nanxing Pain Relief Ointment is an exclusive product of Kangyuan Pharmaceutical.
It is used for joint pain, swelling, impaired activity, and aggravated cold due to cold and dampness.
According to data from Meinenet, in 2020, the sales of compound Nanxing Analgesic Ointment in public medical institutions in China will exceed 300 million yuan, a year-on-year increase of 10.
63%.
According to the annual report of Kangyuan Pharmaceutical, the company's current main product lines focus on viral infectious diseases, gynecological diseases, cardiovascular and cerebrovascular diseases, orthopedic and traumatological diseases and other advantageous fields of traditional Chinese medicine.
In 2020, the company's orthopedics and traumatology products will increase by nearly 10% year-on-year.
Among them, the compound Nanxing Pain Relief Ointment and Yaobitong Capsules had better growth.
It is used for joint pain, swelling, impaired activity, and aggravated cold due to cold and dampness.
According to data from Meinenet, in 2020, the sales of compound Nanxing Analgesic Ointment in public medical institutions in China will exceed 300 million yuan, a year-on-year increase of 10.
63%.
According to the annual report of Kangyuan Pharmaceutical, the company's current main product lines focus on viral infectious diseases, gynecological diseases, cardiovascular and cerebrovascular diseases, orthopedic and traumatological diseases and other advantageous fields of traditional Chinese medicine.
In 2020, the company's orthopedics and traumatology products will increase by nearly 10% year-on-year.
Among them, the compound Nanxing Pain Relief Ointment and Yaobitong Capsules had better growth.
Sales of terminal musk zuifeng analgesic ointment in China's public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
Musk Zhuifeng Pain Relief Ointment is the exclusive product of Chongqing Xi'an Pharmaceutical.
It is used for joint, muscle pain and sprain pain caused by cold and damp arthralgia.
This product has many auras such as national medical insurance, national basic medicine, and traditional Chinese medicine protection.
According to data from Meinnet.
com, the sales growth rate of musk zuifeng analgesic ointment in Chinese public medical institutions in recent years has exceeded 10%, and it will increase by 35.
74% in 2020.
It is used for joint, muscle pain and sprain pain caused by cold and damp arthralgia.
This product has many auras such as national medical insurance, national basic medicine, and traditional Chinese medicine protection.
According to data from Meinnet.
com, the sales growth rate of musk zuifeng analgesic ointment in Chinese public medical institutions in recent years has exceeded 10%, and it will increase by 35.
74% in 2020.
Sales of musk bone-strengthening ointment in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in recent years, the sales of musk bone-strengthening ointment in public medical institutions in China have exceeded 100 million yuan.
In 2020, it will be ranked among the top 10 products with a growth rate of over 20%.
Musk bone-strengthening ointment has fierce competition, with more than 50 manufacturers with production approvals.
Among them, Huangshi Sanitary Materials Pharmaceutical has the largest market share, exceeding 35%; Shenyang Guancheng Pharmaceutical, Huangshi Likang Pharmaceutical, and Zhanjiang Jimin Pharmaceutical have market shares of more than 10%.
com, in recent years, the sales of musk bone-strengthening ointment in public medical institutions in China have exceeded 100 million yuan.
In 2020, it will be ranked among the top 10 products with a growth rate of over 20%.
Musk bone-strengthening ointment has fierce competition, with more than 50 manufacturers with production approvals.
Among them, Huangshi Sanitary Materials Pharmaceutical has the largest market share, exceeding 35%; Shenyang Guancheng Pharmaceutical, Huangshi Likang Pharmaceutical, and Zhanjiang Jimin Pharmaceutical have market shares of more than 10%.
Source: Mi Nei.
com database, announcement of listed companies
com database, announcement of listed companies
According to the latest data from Meinenet.
com on May 27th, the market for proprietary Chinese medicine plasters in public medical institutions in China has been steadily rising in recent years.
Although affected by the new crown epidemic in 2020, it will still achieve a year-on-year increase of 7.
29%.
The sales of TOP10 products all exceed 100 million yuan, accounting for more than 70% of the market share of proprietary Chinese medicine plasters, and the market concentration is relatively high.
Among them, Yunnan Baiyao ointment sales reached a new high after breaking through the 1 billion mark in 2019; Xiaotong Plaster followed closely and became the second product exceeding 1 billion.
From the perspective of growth rate, 6 products including Yunnan Baiyao Ointment, Xiaotong Plaster, and Compound Nanxing Pain Relief Ointment all exceeded 10%.
It is worth mentioning that 7 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other companies.
com on May 27th, the market for proprietary Chinese medicine plasters in public medical institutions in China has been steadily rising in recent years.
Although affected by the new crown epidemic in 2020, it will still achieve a year-on-year increase of 7.
29%.
The sales of TOP10 products all exceed 100 million yuan, accounting for more than 70% of the market share of proprietary Chinese medicine plasters, and the market concentration is relatively high.
Among them, Yunnan Baiyao ointment sales reached a new high after breaking through the 1 billion mark in 2019; Xiaotong Plaster followed closely and became the second product exceeding 1 billion.
From the perspective of growth rate, 6 products including Yunnan Baiyao Ointment, Xiaotong Plaster, and Compound Nanxing Pain Relief Ointment all exceeded 10%.
It is worth mentioning that 7 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other companies.
TOP10 Chinese patent medicinal plasters are released! Qizheng, Lingrui.
.
.
7 exclusive products "Baping"
.
.
7 exclusive products "Baping"
Sales of proprietary Chinese medicine patches in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in recent years , the sales of proprietary Chinese medicine plasters in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased.
In 2020, despite the impact of the new crown epidemic, they still To achieve a year-on-year increase of 7.
29%.
From the perspective of sales channels, the market share of urban public hospitals, county-level public hospitals, and township hospitals all declined slightly, while urban community centers grew rapidly.
com, in recent years , the sales of proprietary Chinese medicine plasters in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased.
In 2020, despite the impact of the new crown epidemic, they still To achieve a year-on-year increase of 7.
29%.
From the perspective of sales channels, the market share of urban public hospitals, county-level public hospitals, and township hospitals all declined slightly, while urban community centers grew rapidly.
2020 Top 10 Chinese Patent Medicine Plaster Products in Public Medical Institutions in China's Urban Public Medical Institutions
Source: Terminal competition landscape of China's public medical institutions
The sales of TOP10 products all exceed 100 million yuan, accounting for more than 70% of the market share of proprietary Chinese medicine plasters, and the market concentration is relatively high.
Among them, the sales of Yunnan Baiyao ointment broke the 1 billion mark in 2019 and reached a new high in 2020; Xiaotong Plaster followed closely and became the second product exceeding 1 billion.
From the perspective of treatment category, orthopedic analgesics accounted for half of the country.
It is worth mentioning that 7 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other companies.
Among them, the sales of Yunnan Baiyao ointment broke the 1 billion mark in 2019 and reached a new high in 2020; Xiaotong Plaster followed closely and became the second product exceeding 1 billion.
From the perspective of treatment category, orthopedic analgesics accounted for half of the country.
It is worth mentioning that 7 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other companies.
Yunnan Baiyao Ointment hit a new high! The second 1 billion Chinese patent medicine plaster was born
Sales of Yunnan Baiyao Ointment in Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Yunnan Baiyao Ointment is an exclusive product of Yunnan Baiyao, which is used for bruises, blood stasis, swelling pain, and rheumatic pain.
According to data from Menet.
com, after the sales of Yunnan Baiyao Ointment in China's public medical institutions exceeded the 1 billion mark in 2019, it will hit a new high in 2020, with a year-on-year increase of more than 15%.
According to data from Menet.
com, after the sales of Yunnan Baiyao Ointment in China's public medical institutions exceeded the 1 billion mark in 2019, it will hit a new high in 2020, with a year-on-year increase of more than 15%.
Recently, the official website of Yunnan Baiyao announced that the company has signed a strategic cooperation framework agreement with Shanghai Pharmaceuticals and Tianjin Pharmaceuticals, and plans to establish a "Yuntian • Rejuvenation of China's Excellent Traditional Chinese Medicine Industry Alliance" to jointly develop the Chinese medicine industry.
Dong Ming, CEO of Yunnan Baiyao, said that this strategic cooperation is of great significance to the development of the Chinese medicine industry.
The development of the Chinese medicine business of the three companies has their own advantages, outstanding characteristics, and complements each other.
They will give full play to the synergy effect through strategic cooperation.
From a strategic perspective, we will carry out multi-dimensional cooperation in research, planting, production, and sales to promote the rapid development of corporate business.
At the same time, through the superposition of brand influence, the improvement of the quality standard and evaluation system of Chinese medicine, the joint research and development of the Chinese medicine industry, the innovation of Chinese medicine health products, etc.
, it injects a booster for the development of the Chinese medicine industry and contributes to the development of the Chinese medicine industry.
The national business card contributes its due strength.
Dong Ming, CEO of Yunnan Baiyao, said that this strategic cooperation is of great significance to the development of the Chinese medicine industry.
The development of the Chinese medicine business of the three companies has their own advantages, outstanding characteristics, and complements each other.
They will give full play to the synergy effect through strategic cooperation.
From a strategic perspective, we will carry out multi-dimensional cooperation in research, planting, production, and sales to promote the rapid development of corporate business.
At the same time, through the superposition of brand influence, the improvement of the quality standard and evaluation system of Chinese medicine, the joint research and development of the Chinese medicine industry, the innovation of Chinese medicine health products, etc.
, it injects a booster for the development of the Chinese medicine industry and contributes to the development of the Chinese medicine industry.
The national business card contributes its due strength.
Sales of terminal pain relief plasters in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
Xiaotong Plaster is an exclusive product of Qizheng Tibetan Medicine, which is mainly used for acute and chronic sprains, bruises, bruises, bone hyperplasia, rheumatism and rheumatoid pain.
According to data from Menet.
com, the sales of terminal pain relief plasters in public medical institutions in China have grown steadily in recent years, and will exceed the 1 billion mark in 2020.
According to data from Menet.
com, the sales of terminal pain relief plasters in public medical institutions in China have grown steadily in recent years, and will exceed the 1 billion mark in 2020.
，2021“”，“”，，，，。，，、，，，，；，，。，、，，O2O、，。，，，、、、。“”、“”，，，。
10%！、6
6
：
，TOP10，、、610%。，4，，30%。
：
，、、、。，20203，10.
63%。，、、、，202010%，，、。
63%。，、、、，202010%，，、。
Sales of terminal musk zuifeng analgesic ointment in China's public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
Musk Zhuifeng Pain Relief Ointment is the exclusive product of Chongqing Xi'an Pharmaceutical.
It is used for joint, muscle pain and sprain pain caused by cold and damp arthralgia.
This product has many auras such as national medical insurance, national basic medicine, and traditional Chinese medicine protection.
According to data from Meinnet.
com, the sales growth rate of musk zuifeng analgesic ointment in Chinese public medical institutions in recent years has exceeded 10%, and it will increase by 35.
74% in 2020.
It is used for joint, muscle pain and sprain pain caused by cold and damp arthralgia.
This product has many auras such as national medical insurance, national basic medicine, and traditional Chinese medicine protection.
According to data from Meinnet.
com, the sales growth rate of musk zuifeng analgesic ointment in Chinese public medical institutions in recent years has exceeded 10%, and it will increase by 35.
74% in 2020.
Sales of musk bone-strengthening ointment in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in recent years, the sales of musk bone-strengthening ointment in public medical institutions in China have exceeded 100 million yuan.
In 2020, it will be ranked among the top 10 products with a growth rate of over 20%.
Musk bone-strengthening ointment has fierce competition, with more than 50 manufacturers with production approvals.
Among them, Huangshi Sanitary Materials Pharmaceutical has the largest market share, exceeding 35%; Shenyang Guancheng Pharmaceutical, Huangshi Likang Pharmaceutical, and Zhanjiang Jimin Pharmaceutical have market shares of more than 10%.
com, in recent years, the sales of musk bone-strengthening ointment in public medical institutions in China have exceeded 100 million yuan.
In 2020, it will be ranked among the top 10 products with a growth rate of over 20%.
Musk bone-strengthening ointment has fierce competition, with more than 50 manufacturers with production approvals.
Among them, Huangshi Sanitary Materials Pharmaceutical has the largest market share, exceeding 35%; Shenyang Guancheng Pharmaceutical, Huangshi Likang Pharmaceutical, and Zhanjiang Jimin Pharmaceutical have market shares of more than 10%.
Source: Mi Nei.
com database, announcement of listed companies
com database, announcement of listed companies
According to the latest data from Meinenet.
com on May 27th, the market for proprietary Chinese medicine plasters in public medical institutions in China has been steadily rising in recent years.
Although affected by the new crown epidemic in 2020, it will still achieve a year-on-year increase of 7.
29%.
The sales of TOP10 products all exceed 100 million yuan, accounting for more than 70% of the market share of proprietary Chinese medicine plasters, and the market concentration is relatively high.
Among them, Yunnan Baiyao ointment sales reached a new high after breaking through the 1 billion mark in 2019; Xiaotong Plaster followed closely and became the second product exceeding 1 billion.
From the perspective of growth rate, 6 products including Yunnan Baiyao Ointment, Xiaotong Plaster, and Compound Nanxing Pain Relief Ointment all exceeded 10%.
It is worth mentioning that 7 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other companies.
com on May 27th, the market for proprietary Chinese medicine plasters in public medical institutions in China has been steadily rising in recent years.
Although affected by the new crown epidemic in 2020, it will still achieve a year-on-year increase of 7.
29%.
The sales of TOP10 products all exceed 100 million yuan, accounting for more than 70% of the market share of proprietary Chinese medicine plasters, and the market concentration is relatively high.
Among them, Yunnan Baiyao ointment sales reached a new high after breaking through the 1 billion mark in 2019; Xiaotong Plaster followed closely and became the second product exceeding 1 billion.
From the perspective of growth rate, 6 products including Yunnan Baiyao Ointment, Xiaotong Plaster, and Compound Nanxing Pain Relief Ointment all exceeded 10%.
It is worth mentioning that 7 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other companies.
TOP10 Chinese patent medicinal plasters are released! Qizheng, Lingrui.
.
.
7 exclusive products "Baping"
TOP10 Chinese patent medicinal plasters are released! Qizheng, Lingrui. .
.
7 exclusive products "Baping"
.
.
7 exclusive products "Baping"
Sales of proprietary Chinese medicine patches in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in recent years , the sales of proprietary Chinese medicine plasters in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased.
In 2020, despite the impact of the new crown epidemic, they still To achieve a year-on-year increase of 7.
29%.
From the perspective of sales channels, the market share of urban public hospitals, county-level public hospitals, and township hospitals all declined slightly, while urban community centers grew rapidly.
Hospital hospital hospitalcom, in recent years , the sales of proprietary Chinese medicine plasters in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased.
In 2020, despite the impact of the new crown epidemic, they still To achieve a year-on-year increase of 7.
29%.
From the perspective of sales channels, the market share of urban public hospitals, county-level public hospitals, and township hospitals all declined slightly, while urban community centers grew rapidly.
2020 Top 10 Chinese Patent Medicine Plaster Products in Public Medical Institutions in China's Urban Public Medical Institutions
Source: Terminal competition landscape of China's public medical institutions
The sales of TOP10 products all exceed 100 million yuan, accounting for more than 70% of the market share of proprietary Chinese medicine plasters, and the market concentration is relatively high.
Among them, the sales of Yunnan Baiyao ointment broke the 1 billion mark in 2019 and reached a new high in 2020; Xiaotong Plaster followed closely and became the second product exceeding 1 billion.
From the perspective of treatment category, orthopedic analgesics accounted for half of the country.
It is worth mentioning that 7 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other companies.
Among them, the sales of Yunnan Baiyao ointment broke the 1 billion mark in 2019 and reached a new high in 2020; Xiaotong Plaster followed closely and became the second product exceeding 1 billion.
From the perspective of treatment category, orthopedic analgesics accounted for half of the country.
It is worth mentioning that 7 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other companies.
Yunnan Baiyao Ointment hit a new high! The second 1 billion Chinese patent medicine plaster was born
Yunnan Baiyao Ointment hit a new high! The second 1 billion Chinese patent medicine plaster was born Sales of Yunnan Baiyao Ointment in Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Yunnan Baiyao Ointment is an exclusive product of Yunnan Baiyao, which is used for bruises, blood stasis, swelling pain, and rheumatic pain.
According to data from Menet.
com, after the sales of Yunnan Baiyao Ointment in China's public medical institutions exceeded the 1 billion mark in 2019, it will hit a new high in 2020, with a year-on-year increase of more than 15%.
According to data from Menet.
com, after the sales of Yunnan Baiyao Ointment in China's public medical institutions exceeded the 1 billion mark in 2019, it will hit a new high in 2020, with a year-on-year increase of more than 15%.
Recently, the official website of Yunnan Baiyao announced that the company has signed a strategic cooperation framework agreement with Shanghai Pharmaceuticals and Tianjin Pharmaceuticals, and plans to establish a "Yuntian • Rejuvenation of China's Excellent Traditional Chinese Medicine Industry Alliance" to jointly develop the Chinese medicine industry.
Dong Ming, CEO of Yunnan Baiyao, said that this strategic cooperation is of great significance to the development of the Chinese medicine industry.
The development of the Chinese medicine business of the three companies has their own advantages, outstanding characteristics, and complements each other.
They will give full play to the synergy effect through strategic cooperation.
From a strategic perspective, we will carry out multi-dimensional cooperation in research, planting, production, and sales to promote the rapid development of corporate business.
At the same time, through the superposition of brand influence, the improvement of the quality standard and evaluation system of Chinese medicine, the joint research and development of the Chinese medicine industry, the innovation of Chinese medicine health products, etc.
, it injects a booster for the development of the Chinese medicine industry and contributes to the development of the Chinese medicine industry.
The national business card contributes its due strength.
Medicine medicine medicine Chinese medicine Chinese medicine Chinese medicine business enterprise business health health healthDong Ming, CEO of Yunnan Baiyao, said that this strategic cooperation is of great significance to the development of the Chinese medicine industry.
The development of the Chinese medicine business of the three companies has their own advantages, outstanding characteristics, and complements each other.
They will give full play to the synergy effect through strategic cooperation.
From a strategic perspective, we will carry out multi-dimensional cooperation in research, planting, production, and sales to promote the rapid development of corporate business.
At the same time, through the superposition of brand influence, the improvement of the quality standard and evaluation system of Chinese medicine, the joint research and development of the Chinese medicine industry, the innovation of Chinese medicine health products, etc.
, it injects a booster for the development of the Chinese medicine industry and contributes to the development of the Chinese medicine industry.
The national business card contributes its due strength.
Sales of terminal pain relief plasters in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
Xiaotong Plaster is an exclusive product of Qizheng Tibetan Medicine, which is mainly used for acute and chronic sprains, bruises, bruises, bone hyperplasia, rheumatism and rheumatoid pain.
According to data from Menet.
com, the sales of terminal pain relief plasters in public medical institutions in China have grown steadily in recent years, and will exceed the 1 billion mark in 2020.
According to data from Menet.
com, the sales of terminal pain relief plasters in public medical institutions in China have grown steadily in recent years, and will exceed the 1 billion mark in 2020.
Qizheng Tibetan Medicine pointed out in its annual report that in 2021, the company will continue to promote and deepen the strategic layout of “one axis, two wings and three supports”, with the mission of “strengthening pain relief”, accelerating market coverage and channel sinking, and strengthening refined management And organization building, guided by academics and brand, continuously improve the quality of operation to ensure the sustainable development of the business.
In terms of products, on the basis of Xiaotong Plaster as a strategic product, develop two major products, Baimai Ointment and Qingpeng Ointment, to expand the market share of Tiebanghammer Discrete Plaster, enrich the product portfolio of different channels, and incubate new pain-relieving products Ruyi Treasure Pills, expand the field of analgesia; strengthen the terminal coverage and academic promotion of women and children's products represented by Honghua Ruyi Pills, and combine a series of oral Tibetan medicines to continue to promote the superior therapeutic products of Tibetan medicine.
In terms of channels, we will strengthen urban expansion, channel sinking, develop county and community medical markets, deepen O2O and e-commerce channels, build an online product supply chain system, and establish a diversified business cooperation model layout for online channels.
In terms of marketing model, strengthen the two-wheel drive of academic marketing and brand marketing, further explore online digital marketing models, and consolidate and develop the company's position in the fields of skeletal muscle system, skin, rehabilitation, women and children.
Continue to promote the "Stomach" family digestive system products and the "Lung-protecting" family respiratory system products, integrate the featured diagnosis and treatment plans of Tibetan medicine's dominant diseases, and provide customers with a full range of diagnosis and treatment plans to achieve the common growth of the company's full range of products.
In terms of products, on the basis of Xiaotong Plaster as a strategic product, develop two major products, Baimai Ointment and Qingpeng Ointment, to expand the market share of Tiebanghammer Discrete Plaster, enrich the product portfolio of different channels, and incubate new pain-relieving products Ruyi Treasure Pills, expand the field of analgesia; strengthen the terminal coverage and academic promotion of women and children's products represented by Honghua Ruyi Pills, and combine a series of oral Tibetan medicines to continue to promote the superior therapeutic products of Tibetan medicine.
In terms of channels, we will strengthen urban expansion, channel sinking, develop county and community medical markets, deepen O2O and e-commerce channels, build an online product supply chain system, and establish a diversified business cooperation model layout for online channels.
In terms of marketing model, strengthen the two-wheel drive of academic marketing and brand marketing, further explore online digital marketing models, and consolidate and develop the company's position in the fields of skeletal muscle system, skin, rehabilitation, women and children.
Continue to promote the "Stomach" family digestive system products and the "Lung-protecting" family respiratory system products, integrate the featured diagnosis and treatment plans of Tibetan medicine's dominant diseases, and provide customers with a full range of diagnosis and treatment plans to achieve the common growth of the company's full range of products.
Over 10% ! The 6 major products of Compound Nanxing Pain Relief Ointment and Musk Zhuifeng Pain Relief Ointment are growing rapidly
Over 10% ! The 6 major products of Compound Nanxing Pain Relief Ointment and Musk Zhuifeng Pain Relief Ointment are growing rapidly 6 product related information
Source: One-click search on Mi Nei.
com
com
In terms of growth rate, among the TOP10 products, the growth rates of 6 products including Yunnan Baiyao Ointment, Xiaotong Plaster, and Compound Nanxing Pain Relief Ointment all exceeded 10%.
Among them, 4 are exclusive products.
Musk Zhuifeng Analgesic Ointment has the fastest growth rate, exceeding 30%.
Among them, 4 are exclusive products.
Musk Zhuifeng Analgesic Ointment has the fastest growth rate, exceeding 30%.
Sales of Compound Nanxing Pain Relief Ointment on the Terminal of Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Compound Nanxing Pain Relief Ointment is an exclusive product of Kangyuan Pharmaceutical.
It is used for joint pain, swelling, impaired activity, and aggravated cold due to cold and dampness.
According to data from Meinenet, in 2020, the sales of compound Nanxing Analgesic Ointment in public medical institutions in China will exceed 300 million yuan, a year-on-year increase of 10.
63%.
According to the annual report of Kangyuan Pharmaceutical, the company's current main product lines focus on viral infectious diseases, gynecological diseases, cardiovascular and cerebrovascular diseases, orthopedic and traumatological diseases and other advantageous fields of traditional Chinese medicine.
In 2020, the company's orthopedics and traumatology products will increase by nearly 10% year-on-year.
Among them, the compound Nanxing Pain Relief Ointment and Yaobitong Capsules had better growth.
It is used for joint pain, swelling, impaired activity, and aggravated cold due to cold and dampness.
According to data from Meinenet, in 2020, the sales of compound Nanxing Analgesic Ointment in public medical institutions in China will exceed 300 million yuan, a year-on-year increase of 10.
63%.
According to the annual report of Kangyuan Pharmaceutical, the company's current main product lines focus on viral infectious diseases, gynecological diseases, cardiovascular and cerebrovascular diseases, orthopedic and traumatological diseases and other advantageous fields of traditional Chinese medicine.
In 2020, the company's orthopedics and traumatology products will increase by nearly 10% year-on-year.
Among them, the compound Nanxing Pain Relief Ointment and Yaobitong Capsules had better growth.
Sales of terminal musk zuifeng analgesic ointment in China's public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
Musk Zhuifeng Pain Relief Ointment is the exclusive product of Chongqing Xi'an Pharmaceutical.
It is used for joint, muscle pain and sprain pain caused by cold and damp arthralgia.
This product has many auras such as national medical insurance, national basic medicine, and traditional Chinese medicine protection.
According to data from Meinnet.
com, the sales growth rate of musk zuifeng analgesic ointment in Chinese public medical institutions in recent years has exceeded 10%, and it will increase by 35.
74% in 2020.
It is used for joint, muscle pain and sprain pain caused by cold and damp arthralgia.
This product has many auras such as national medical insurance, national basic medicine, and traditional Chinese medicine protection.
According to data from Meinnet.
com, the sales growth rate of musk zuifeng analgesic ointment in Chinese public medical institutions in recent years has exceeded 10%, and it will increase by 35.
74% in 2020.
Sales of musk bone-strengthening ointment in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in recent years, the sales of musk bone-strengthening ointment in public medical institutions in China have exceeded 100 million yuan.
In 2020, it will be ranked among the top 10 products with a growth rate of over 20%.
Musk bone-strengthening ointment has fierce competition, with more than 50 manufacturers with production approvals.
Among them, Huangshi Sanitary Materials Pharmaceutical has the largest market share, exceeding 35%; Shenyang Guancheng Pharmaceutical, Huangshi Likang Pharmaceutical, and Zhanjiang Jimin Pharmaceutical have market shares of more than 10%.
com, in recent years, the sales of musk bone-strengthening ointment in public medical institutions in China have exceeded 100 million yuan.
In 2020, it will be ranked among the top 10 products with a growth rate of over 20%.
Musk bone-strengthening ointment has fierce competition, with more than 50 manufacturers with production approvals.
Among them, Huangshi Sanitary Materials Pharmaceutical has the largest market share, exceeding 35%; Shenyang Guancheng Pharmaceutical, Huangshi Likang Pharmaceutical, and Zhanjiang Jimin Pharmaceutical have market shares of more than 10%.
Source: Mi Nei.
com database, announcement of listed companies
com database, announcement of listed companies
